Moxibustion Reduces Symptoms and Improves Quality of Life in Patients With Allergic Rhinitis

Study Overview
=================
Brief Summary
-----------------
The objective of this randomized controlled clinical trial is to compare the therapeutic effect of moxibustion on allergic rhinitis. The main questions it aims to answer are: Based on randomized controlled trials, verify the effectiveness of moxibustion in treating allergic rhinitis Based on a real-time monitoring system for human surface temperature, discuss the differences in therapeutic effects of different moxibustion doses on allergic rhinitis

Detailed Description
-----------------
Allergic rhinitis has a high incidence and is difficult to cure, seriously affecting the quality of life of patients Compare the effects of different moxibustion durations on the clinical efficacy and body surface temperature of patients with allergic rhinitis, and preliminarily explore the impact of different moxibustion doses on the efficacy of heavy moxibustion treatment for allergic rhinitis, providing evidence-based basis for clinical practice.

Official Title
-----------------
The Therapeutic Effect and Standardization of Moxibustion in the Treatment of Allergic Rhinitis

Conditions
-----------------
Allergic Rhinitis

Intervention / Treatment
-----------------
* Behavioral: Ordinary moxibustion volume group
* Behavioral: First group of heavy moxibustion
* Behavioral: Second groups of heavy moxibustion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Those who meet the diagnostic criteria of Chinese and Western medicine for AR; Age range from 18 to 75 years old, regardless of gender; Patients and their families are informed and agree to the study. Exclusion criteria Those who are undergoing other traditional Chinese medicine external treatment methods; Those who have taken traditional Chinese medicine recently or during treatment; Individuals who are allergic to heavy moxibustion smoke and dust; Individuals with concomitant bronchial asthma or other respiratory system diseases; Patients with severe skin diseases or ulcers in the local area where moxibustion is applied; Pregnant and lactating patients; Patients with severe diseases of important organs such as the heart, liver, lungs, and kidneys; Those who are unable to receive treatment according to regulations due to inconvenience in work, study, transportation, or personal activities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Ordinary moxibustion volume group<br> | Behavioral: Ordinary moxibustion volume group<br>* Moxibustion for 10 minutes per acupoint<br>|
| Experimental: First group of heavy moxibustion<br> | Behavioral: First group of heavy moxibustion<br>* Moxibustion for 20 minutes per acupoint<br>|
| Experimental: Second groups of heavy moxibustion<br> | Behavioral: Second groups of heavy moxibustion<br>* Moxibustion for 30 minutes per acupoint<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rhinitis VAS Visual Analog Scale（AR-VAS） | VAS will be used to evaluate the relief of rhinitis symptoms, with a total score of 0-10. The higher the score, the more severe the symptoms will be | Change from baseline VAS scores at week 0(before treatment)，4 and 12. | 
| Total nasal symptom scores（TNSS） | The main symptoms of allergic rhinitis, the higher the score, the worse the condition | Change from baseline TNSS scores at week 0(before treatment)，4 and 12. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total non nasal symptom scores（TNNSS） | The nasal accompanying symptoms of allergic rhinitis, qualitative evaluation of the severity of the disease, with some indicating severity and none indicating milder severity | Change from baseline TNNSS scores at week0(before treatment)，4 and 12. | 
| Rhino-conjunctivitis Quality of Life Questionnaire （RQLQ） | RQLQ consists of 28 items, including daily life (1-3), sleep (4-6), non nasal eye symptoms (7-13), life problems (14-16), nasal symptoms (17-20), eye symptoms (21-24), and emotions (25-28). In the 7-point system, 1 point is the best and 7 points are the worst. | Change from baseline RQLQ scores at week0(before treatment)，4 and 12. | 
| Detection of serum IgE and IL-33 levels | Immunoglobulin IgE and serum inflammatory cytokine IL-33 levels | Week0(before treatment), week 4（after treatment）. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
allergic rhinitis, moxibustion, body surface temperature